12 Apr

Venetoclax rituximab is superior to Bendamustin rituximab in progression-free survival in patients with recurrent or refractory CLL. A Phase III study was published in the New England Journal of Medicine (NEJM) on March 22, 2018 in which a total of n = 389 patients with recurrent...

12 Apr

GermanOncology is currently conducting a survey on "ß-thalassaemia and sickle cell disease" among haematologists/oncologists in private practice, on behalf of an American biotech company. This survey aims to gain a better understanding of the patient flow among patients with thalassemia and sickle cell disease, and...